HL-1186 placebo

DRUG6 trials

Sponsors

Shanghai Yidian Pharmaceutical Technology Development Co., Ltd., Shanghai Huilun Pharmaceutical Co., Ltd.

Conditions

Diabetic Peripheral Neuropathic PainHealthy ParticipantsModerate to Severe Acute Postoperative PainPostoperative Pain

Phase 1

Assess the Safety, Tolerability, and Pharmacokinetics of HL-1186 in Healthy Participants

RecruitingNCT06912295

Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.Healthy Participants

Start: 2025-03-21End: 2025-10-09Target: 76Updated: 2025-08-24

Phase 2

Evaluate the Safety and Efficacy of HL-1186 Tablet for Moderate to Severe Acute Pain After Surgery

RecruitingNCT07147049

Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.Moderate to Severe Acute Postoperative Pain

Start: 2025-08-08End: 2026-01-31Target: 72Updated: 2025-12-22

Evaluate the Efficacy and Safety of HL-1186 in Patients With Diabetic Peripheral Neuropathic Pain

Not yet recruitingNCT07159243

Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.Diabetic Peripheral Neuropathic Pain

Start: 2025-09-30End: 2026-10-31Target: 180Updated: 2025-09-08

Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Pain Management in Abdominal Surgery

RecruitingNCT07311369

Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.Moderate to Severe Acute Postoperative Pain

Start: 2025-12-31End: 2026-03-31Target: 40Updated: 2025-12-30

Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Analgesia in Orthopedic Surgery

RecruitingNCT07699601

Shanghai Huilun Pharmaceutical Co., Ltd.Postoperative Pain

Start: 2026-05-09End: 2026-12-01Target: 330Updated: 2026-07-13

Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Analgesia in Abdominal Surgery

RecruitingNCT07709598

Shanghai Huilun Pharmaceutical Co., Ltd.Postoperative Pain

Start: 2026-05-11End: 2026-12-01Target: 330Updated: 2026-07-16